HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing In Brief

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder: DayWear Plus Multi-Protection Anti-Oxidant Lotion SPF 30 provides a combination of "potent antioxidants, plus intense hydrators and an enhanced SPF 30 sunscreen that defends the skin against age-accelerating free radicals while helping the skin to improve its own natural defense system," Estee Lauder claims. Launching in April, the lotion contains white birch extract, a botanical that helps reactivate anti-stress proteins that weaken with age, as well as antioxidants white tea extract, South African red tea and grape seed extract, firm says. Lotion joins other DayWear Plus skin care products, including Multi-Protection Anti-Oxidant Lotion SPF 15 and Multi-Protection Anti-Oxidant Eye Crème...
Advertisement

Related Content

Dove Spreads Its Wings With Hair Styling, Anti-Aging Skin Care
Dove Spreads Its Wings With Hair Styling, Anti-Aging Skin Care
Advertisement
UsernamePublicRestriction

Register

RS013816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel